=== PAGE 4 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Fabio Almeida, MD
Phoenix Molecular Imaging
(b) (4) / MA 1

                                                                                Page 4

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266.** A courtesy copy can be sent by
facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the
full address above and include a prominent directional notation (e.g., a sticker) to indicate that
the submission is intended for OPDP. Please refer to MA 1 in addition to the IND number in
all future correspondence relating to this particular matter. All correspondence should include
a subject line that clearly identifies the submission as a Response to Untitled Letter. OPDP
reminds you that only written communications are considered official.

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for 11C-Acetate comply with
each applicable requirement of the FD&C Act and FDA implementing regulations.

                                                          Sincerely,

                                              {See appended electronic signature page}

                                              David Foss, PharmD, MPH, BCPS
                                              Regulatory Review Officer
                                              Division of Advertising & Promotion Review 2
                                              Office of Prescription Promotion

                                              {See appended electronic signature page}

                                              James Dvorsky, PharmD, RAC, CPH
                                              Team Leader
                                              Division of Advertising & Promotion Review 2
                                              Office of Prescription Drug Promotion

Reference ID: 4391928
